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Abstract 
 
Orodispersible tablets (ODTs), also known as fast melt, quick melts, 
fast disintegrating have the unique property of disintegrating in the 
mouth in seconds without chewing and the need of water. The 
purpose of this investigation was to develop mouth dissolving tablets 
of aceclofenac using KYRON T-314 (Polacrillin Potassium) as a 
novel superdisintegrant. Mouth dissolving tablets of aceclofenac 
were prepared by wet granulation technique using KYRON T-314 as 
superdisintegrant and menthol as subliming agent. The present study 
demonstrated potentials for rapid absorption, improved 
bioavailability, effective therapy and patient compliance. 
Keywords: KYRON T-314, Mouth dissolving tablet, Aceclofenac, 
Subliming agent, Superdisintegrant. 
 
Introduction 
The tablet is the most widely used dosage form 
because of its convenience in terms of self-
administration, compactness and ease in 
manufacturing. However, geriatric and paediatric 
patients experience difficulty in swallowing 
conventional tablets, which leads to poor patient 
compliance. To overcome this weakness, 
scientists have developed innovative drug 
delivery systems known as mouth dissolving 
tablets. Their characteristic advantages such as 
administration without water, anywhere, anytime 
lead to their suitability to geriatric and paediatric 
patients. They are also suitable for the mentally 
ill, the bedridden and patients who do not have 
easy access to water. The benefits, in terms of 
patient compliance, rapid onset of action, 
increased bioavailability and good stability made 
these tablets popular as a dosage form in the 
current market [1-2]. 
 
 
NSAID has been indicated for various painful 
indications  [3] and proved as effective as other 
NSAIDs with lower indications of gastro-
intestinal adverse effects and thus, resulted in a 
greater compliance with treatment [4]. 
Aceclofenac,(2-[2-[2-(2,6 dichlorophenyl) 
aminophenyl] acetyl] oxyacetic acid), a 
nonsteroidal anti-inflammatory, analgesic and 
antipyretic drug used in rheumatoid arthritis, 
post-traumatic pain, masculo-skeletal and joint 
disorders [5]  .  
Aceclofenac is practically insoluble. For poorly 
soluble orally administered drugs, the rate of 
absorption is often controlled by the rate of 
dissolution. The rate of dissolution can be 
increased by increasing the surface area of 
available drug by various methods 
(micronization, complexation and solid 
dispersion). The dissolution of a drug can also be 
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influenced by disintegration time of the tablets. 
Faster disintegration of tablets delivers a fine 
suspension of drug particles resulting in a higher 
surface area and faster dissolution. Polacrillin 
Potassium (KYRON T-314) is 2-methyl-2-
propenoic acid polymer with divinylbenzene, 
potassium salt. It is a cation exchange resin used 
in oral pharmaceutical formulation as a tablet 
superdisintegrant. It appears as a cream colored, 
odorless and tasteless, free flowing powder [6]. 
In the present study, an attempt has been made to 
develop mouth dissolving tablets of aceclofenac 
using novel superdisintegrant and to investigate 
the effect of subliming agent on the release 
profile of the drug. The fundamental principle 
used in the development of the fast-dissolving 
tablet is to maximize its pore structure. 
Researchers have evaluated spray dried materials 
[7] and plastic materials [8] for development of 
such tablets. Vacuum-drying [9-14] and freeze-
drying [15-18] techniques have been also tried by 
researchers to maximize the pore structure of the 
tablet matrix. Freeze drying is cumbersome and 
yields a fragile and hygroscopic product. 
Therefore, a vacuum drying technique was 
adopted in the present investigation after addition 
of a subliming agent to increase porosity of the 
tablets. It is likely that a porous hydrophilic 
matrix will easily pick up the disintegrating 
medium and break quickly.  
 
Material and Methods 
 
Materials 
Aceclofenac and KYRON T-314 were obtained 
as a gift sample from Blue Cross Lab. Ltd, Nasik, 
India. Menthol, Magnessium stearate, Aspartame 
and Mannitol were purchased from local 
authorized dealer. 
 
Method 
Formulation of mouth dissolving tablets of 
aceclofenac 
The orodispersible tablets of aceclofenac were 
prepared using the subliming agent, menthol and 
KYRON T-314 as superdisintegrant, mannitol as 
diluent, aspartame as sweetening agent, alcoholic 
solution of polyvinyl pyrrolidone (PVP K-30) (10 
%w/v) as binder and magnessium stearate with 
talc as flow promoter. The composition of each 
batch is shown in Table 1. 
The raw materials were passed through a 100-
mesh screen prior to mixing. The drug and other 
ingredients were mixed together and a sufficient 
quantity of alcoholic solution of PVP K-30 
(10%w/v) was added and mixed to form a 
coherent mass. The wet mass was granulated 
using sieve no. 12 and regranulated after drying 
Table 1: Composition of different batches of mouth-dissolving tablets of aceclofenac. 
 
Quantities (mg) 
Name of Ingredients 
F1 F2 F3 F4 F5 
Aceclofenac 100 100 100 100 100 
Menthol 20 20 25 25 25 
Kyron T-314 20 20 20 25 25 
Magnessium stearate 5 5 5 5 5 
Mannitol 55 50 45 40 40 
Total 200 200 200 200 200 
  *all the quantities expressed in mg. All batches contained 10% (PVP K-30) in ethyl   alcohol as a binder 
and 2% talc and 1% magnessium stearate. Menthol was sublimed from granules in Batches F1 to F4 and 
from tablets in Batch F5. 
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through sieve no. 16. Granules of the all 
formulations were then dried in a vacuum oven 
(Vertex, VT4810) at 60 0C for 12 h resulting in 
localized drying. The final moisture content of 
the granules was found to be between 1-2%, 
which was determined using an IR moisture 
balance. During drying, the menthol sublimed 
with the formation of a porous structure on the 
surface of the tablet. The dried granules were 
then blended with talc, magnessium stearate and 
compressed into tablets using flat face round 
tooling on a Rimek-I rotary tablet machine 
(Karnavati Engg. Pvt. Ltd, Ahmedabad). 
Sublimation was performed from tablets instead 
of granules at 60 0C in selected batch (F5). 
 
Evaluation of formulated tablets: 
 
Thickness 
Thickness of tablet was determined by using 
vernier calliper (Mitutoya, Model CD-6 CS, 
Japan). 
Hardness [19] 
The crushing strength of the tablets was measured 
using a Monsanto hardness tester (Sheetal 
Scientific Industries, Mumbai, India). Three 
tablets from each formulation batch were tested 
randomly and the average reading noted. 
Friability [19] 
Ten tablets were weighed and placed in a Roche 
friabilator (Electrolab, India). Twenty 
preweighed tablets were rotated at 25 rpm for 4 
min. The tablets were then dedusted and 
reweighed and the percentage of weight loss was 
calculated. The percentage friability of the 
tablets were measured as per the following 
formula, 
Percentage friability =   Initial weight – Final weight    x 100 
                                                    Initial weight 
Weight Variation 
Randomly, twenty tablets were selected after 
compression and the mean weight was 
Table 2: Evaluation of mouth-dissolving tablets of aceclofenac. 
 
 
Parameters 
 
F1 
 
F2 
 
F3 
 
F4 
 
F5 
Hardness (kg/cm2) 3.1±0.30 3.4±0.68 2.9±0.51 3.1±0.63 3.6±0.10 
Friability (%) 0.743±0.04 0.629±0.06 0.637±0.05 0.688±0.04 0.574±0.04 
Weight variation  
(mg) 
204±3 
 
199±2 
 
203±3 
 
197±1 
 
200±1 
 
Thickness (mm) 3.5±0.03 3.4±0.07 3.6±0.05 3.4±0.06 3.5±0.01 
 
Wetting time (s) 38.2±2.5 39.3±1.5 43.6±2.2 39.1±2.0 29.4±1.5 
In vitro dispersion 
time (s) 
68.3±2 62.1±1 56.2±2 53.7±3 41.8±2 
Drug content 99.24±3.24 98.44±2.54 98.60±3.04 98.93±1.81 99.42±1.27 
Drug release in 
5min (%) 
69.03±2 72.17±2 73.72±2.5 75.54±3 78.37±1.5 
Drug release in 
30min (%) 
86.81±1.2 88.11±1.6 88.73±2.5 93.26±2.7 97.25±1.3 
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determined. None of the tablets deviated from the 
average weight by more than ±7.5% (USPXX). 
Drug content 
Twenty tablets were weighed and powdered. An 
amount of the powder equivalent to 100mg of 
aceclofenac was dissolved in 100 ml of pH 7.4 
phosphate buffer, filtered, diluted suitably and 
analyzed for drug content at 274 nm using UV-
Visible Spectrophotometer (UV 160- Shimadzu, 
Japan). 
Wetting time [20] 
A piece of circular tissue paper (8cm) folded 
twice was placed in a Petri dish (Internal 
Diameter = 9cm) containing 10 ml of buffer 
solution simulating saliva pH 6.8. A tablet was 
placed on the paper and the time taken for 
complete wetting was noted. Three tablets from 
each formulation were randomly selected and the 
average wetting time was noted. The results are 
tabulated in Table 2. 
 
In vitro dispersion time [21] 
In vitro dispersion time of prepared tablet was 
done by dropping the tablet in 10 ml measuring 
cylinder containing 6 ml of simulated salivary 
fluid (pH 6.8). Time required for complete 
dispersion of tablet was measured. 
Dissolution Study 
In vitro release of aceclofenac from tablets was 
monitored by using 900 ml of  simulated 
intestinal fluid, SIF (USP phosphate buffer 
solution, pH 7.4) at 37±0.5 0C and 50 rpm using 
programmable dissolution tester [Paddle type, 
model TDT-08L, Electrolab, (USP), India]. 5 ml 
Aliquots were withdrawn at one minute time 
intervals and were replenished immediately with 
the same volume of fresh buffer medium. 
Aliquots, following suitable dilutions, were 
assayed spectrophotometrically (UV-1700, 
Shimadzu, Japan) at 274 nm. 
 
Results and Discussion: 
Mouth dissolving drug delivery is rapidly gaining 
acceptance as an important drug delivery 
technology. In such drug delivery, different 
dosage forms disintegrate rapidly in the patient’s 
mouth within a minute and can be gulped easily 
without need of water. This rapid disintegration 
can be achieved by use of high levels of 
disintegrant and/or effervescent agents along with 
water soluble diluents. Hence, it offers increased 
patient compliance and convenience. Water 
insoluble diluents such as microcrystalline 
cellulose and dicalcium phosphate were omitted 
from the study as they are expected to cause an 
unacceptable feeling of grittiness in the mouth. 
Among the soluble diluents, mannitol was 
selected as a diluent considering its advantages in 
terms of easy availability and negative heat of 
dissolution.  
Table 2 shows that all the formulated tablets 
exhibited low weight variation. Addition of a 
subliming agent had no pronounced effect on 
hardness and increased friability of the tablets. 
The wetting time, in vitro dispersion time of the 
tablets were also considerably reduced in tablets 
(Table 2). The drug content of all the 
formulations was found to be between 98.4- 
99.5% which was within the acceptable limits as 
per USP XXVII. The porous structure is 
responsible for faster water uptake; hence it 
facilitates wicking action of KYRON T-314 in 
bringing about faster disintegration. Tablets with 
lower friability may not break during handling on 
machines and/or shipping. The use of a 
sublimation agent resulted in increased friability 
probably due to increased porosity. In the first 
few attempts (F1-F4), sublimation of menthol 
was performed from granules prior to 
compression into tablets. Batches F1 to F4 
showed good mechanical integrity, but the 
disintegration time was a little longer than the 
arbitrarily chosen value of less than 50 seconds. 
In Batch F5, sublimation was performed after 
compression rather than directly from granules. 
The results shown in Table 2 reveal that 
sublimation of menthol from tablets resulted in 
faster disintegration. The compaction process 
might have caused breakage of porous granules 
and subsequent reduction in porosity. The low 
value of wetting time and disintegration time 
indicate that the porosity of tablets of batch F5 
would be greater than batches F1 to F4.  
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In vitro release studies were carried out using 
USP XXIII tablet dissolution test apparatus 
paddle method at 37±10C, taking 900 ml of 
simulated intestinal fluid (SIF) as dissolution 
medium. Speed of rotation of the paddle was set 
at 50 rpm. Aliquots of 5 ml were withdrawn after 
1, 3, 5, 6, 8, 10, 30 min and analyzed 
spectrophotometrically at 274 nm. The in vitro 
dissolution profile (Fig.1) indicated faster and 
maximum drug release from formulation F5. 
Formulation F5 prepared by direct sublimation of 
menthol from final tablets showed 78.37% drug 
release at the end of 5 min when compared to 
tablets prepared by sublimation of menthol from 
granules. The rapid drug dissolution might be due 
to easy breakdown of particles due to porous 
structure formation after sublimation of menthol 
and rapid absorption of drugs into the dissolution 
medium. 
 
Fig. 1: In vitro release profile of various 
Aceclofenac formulations. 
 
Drug Released from MDT of Aceclofenac
0
20
40
60
80
100
0 5 10 15 20 25 30 35
Time (mins)
%
 R
el
ea
se
d
F1
F2
F3
F4
F5
 
 
Conclusion: 
Polacrillin Potassium (KYRON T-314) is a cation 
exchange resin used in oral pharmaceutical 
formulation it swell rapidly when wetted. In the 
present study we used it as a novel super 
disintegrant and studied the effect of the effect of 
subliming agent on the release profile of the drug. 
From the outcome of this study, it can be 
concluded that sublimation method showed better 
disintegration and drug release. The prepared 
tablets using KYRON T-314 disintegrate within 
few seconds without need of water; thereby 
enhancing the absorption leading to its increased 
bioavailability. Vacuum-drying technique would 
be an effective alternative approach compared 
with the use of more expensive adjuvants in the 
formulation of mouth dissolving tablets. 
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